|
1.Date of the board of directors resolution:2025/08/07
2.Name and title of the managerial officer with permission to
engage in competitive conduct:
Chen, Ying-Chi / Vice President of Sales Division
3.Items of competitive conduct in which the officer is permitted
to engage:
Concurrently serves as the head of a company with the same
or similar business scope as our company.
4.Period of permission to engage in the competitive conduct:
During the period of employment as the managerial officer
of the Company.
5.Circumstances of the resolution (please describe the results
of voting in accordance with Article 32 of the Company Act):
The resolution is unanimously adopted by all directors attending
the meeting.
6.If the permitted competitive conduct belongs to the operator of
a mainland China area enterprise, the name and title of the
managerial officer (if it is not the operator of a mainland
China area enterprise, please enter N/A” below): N/A
7.Company name of the mainland China area enterprise and
the officer's position in the enterprise: N/A
8.Address of the mainland China area enterprise: N/A
9.Operations of the mainland China area enterprise: N/A
10.Impact on the company's finance and business: None
11.If the managerial officer has invested in the mainland China
area enterprise, the monetary amount of the investment and
the officer's shareholding ratio: None
12.Any other matters that need to be specified:
In response to the Company's operational needs and long-term
development, the Board of Directors approved the establishment
of a subsidiary (name yet to be determined) on August 7, 2025.
This subsidiary's primary business is the market development
of active pharmaceutical ingredients (APIs), which is somewhat
related to the Company's business and will have a limited impact
on the Company's financial operations.
|
